Osimertinib plus anlotinib in untreated, EGFR-mutated, advanced non-small-cell lung cancer with concurrent alterations: a multicenter phase II study

Xiaojun Yang, Qinquan Tan, Shiyuan Chen, Jieyun Xie, Yihong Zeng, Ruinian Zheng, Qinglin Tan, Wan Zhang, Churen Yu, Ziying Hong, Xinpei Yu, Guanming Jiang

Open source

DOI: 10.1093/oncolo/oyag344
Published: 2026-08-27
Container: The Oncologist
Publisher: Oxford University Press (OUP)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/oncolo/oyag344,
  title = {Osimertinib plus anlotinib in untreated, EGFR-mutated, advanced non-small-cell lung cancer with concurrent alterations: a multicenter phase II study},
  author = {Xiaojun Yang and Qinquan Tan and Shiyuan Chen and Jieyun Xie and Yihong Zeng and Ruinian Zheng and Qinglin Tan and Wan Zhang and Churen Yu and Ziying Hong and Xinpei Yu and Guanming Jiang},
  year = {2026},
  journal = {The Oncologist},
  doi = {10.1093/oncolo/oyag344},
  url = {https://doi.org/10.1093/oncolo/oyag344}
}

RIS

TY  - JOUR
TI  - Osimertinib plus anlotinib in untreated, EGFR-mutated, advanced non-small-cell lung cancer with concurrent alterations: a multicenter phase II study
AU  - Xiaojun Yang
AU  - Qinquan Tan
AU  - Shiyuan Chen
AU  - Jieyun Xie
AU  - Yihong Zeng
AU  - Ruinian Zheng
AU  - Qinglin Tan
AU  - Wan Zhang
AU  - Churen Yu
AU  - Ziying Hong
AU  - Xinpei Yu
AU  - Guanming Jiang
PY  - 2026
JO  - The Oncologist
DO  - 10.1093/oncolo/oyag344
UR  - https://doi.org/10.1093/oncolo/oyag344
ER  -

APA

Yang, X., Tan, Q., Chen, S., Xie, J., Zeng, Y., Zheng, R., Tan, Q., Zhang, W., Yu, C., Hong, Z., Yu, X., & Jiang, G. (2026). Osimertinib plus anlotinib in untreated, EGFR-mutated, advanced non-small-cell lung cancer with concurrent alterations: a multicenter phase II study. The Oncologist. https://doi.org/10.1093/oncolo/oyag344

Source records

crossref · retrieved 2026-09-25T06:35:45.200Z